TherapeuticsMD (TXMD) Tops Q3 EPS by 4c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.22 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance